RecruitingNCT01762813
Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer
Prospective, Population-based Cohort Collection of Blood Samples and Tumor Tissue From Patients Operated on for Primary or Metastatic Colorectal Cancer
Sponsor
Helse Stavanger HF
Enrollment
1,200 participants
Start Date
Jan 1, 2013
Study Type
OBSERVATIONAL
Conditions
Summary
* A prospective, observational study on clinical outcomes of surgical management of primary and metastatic colorectal cancer * Prospective collection of tissues to explore potential biomarkers in blood and/or primary or secondary cancers and/or normal colon
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Diagnosis of colorectal cancer, primary or metastatic (liver), with a treatment intention of planned curative surgery
- Informed consent to participate
- Age ≥18
Exclusion Criteria1
- failure to provide written informed consent
Interventions
PROCEDUREopen and laparoscopic surgery
Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01762813
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
NCT069922589 locations
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT070717141 location
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations